Filing Flows › Integrated Biopharma (INBP) › Q3 FY26
Integrated Biopharma (INBP) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed May 8, 2026
Integrated Biopharma (INBP) reported revenue of $10.1M for the third quarter fiscal 2026 (Q3 FY26), -28% from a year earlier and -10% from the quarter before. Operating margin was -10.7%, net loss $837K (8.3% of revenue).
Integrated Biopharma, Q3 FY26: revenue $10.1M (-28% year over year), operating margin -10.7%, net loss $837K, operating cash flow $517K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.1M | -10% | -28% |
| Operating profit | −$1.1M | — | -247% |
| Net earnings | −$837K | — | -237% |
| Operating cash flow | $517K | -16% | -16% |
What changed
Revenue was $10.1M in Q3 FY26, down 28% year over year and down 10% from the previous quarter. Contract Manufacturing was the largest line at 97% of revenue. Contract Manufacturing lost $3.6M year over year (down 27%), 95% of the total change.
Operating costs exceeded revenue by $1.1M, an operating margin of -10.7%. The quarter ended with a net loss of $837K, wider than the previous quarter's $762K loss.
Operating cash flow was $517K (down 16% year over year). Non-cash charges added back $68K of depreciation and $50K of share-based compensation. Working capital and other items added $1.2M.
Questions
What was Integrated Biopharma's revenue in the third quarter fiscal 2026?
Integrated Biopharma (INBP) reported revenue of $10.1M for the third quarter fiscal 2026 (Q3 FY26), -28% from a year earlier and -10% from the quarter before.
Was Integrated Biopharma profitable in the third quarter fiscal 2026?
Operating loss was $1.1M (-10.7% of revenue) and net loss $837K.